Melbourne, Australia; Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that treatment with its novel antibody-targeted DEP^® conjugate resulted in complete tumour regression and 100% survival in an ovarian cancer model. 

Starpharma’s antibody-targeted DEP™ conjugate (using Herceptin as the targeting group) significantly outperformed both Roche’s Kadcyla^® (T-DM1), a Herceptin^® antibody-drug conjugate (ADC), and the monoclonal antibody Herceptin^® (Trastuzumab) itself in the pre-clinical ovarian cancer model.

Download ASX Announcement: Targeted DEP outperforms leading treatments in ovarian cancer model (pdf file, 302kb)